Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL

NCT02232516 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02232516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02232516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2015
Completion date
March 16, 2024
Enrollment
30 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, stage i cutaneous t-cell non-hodgkin lymphoma, stage ia mycosis fungoides/sezary syndrome, stage ib mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage iia mycosis fungoides/sezary syndrome, stage iib mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iiia mycosis fungoides/sezary syndrome, stage iiib mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iva mycosis fungoides/sezary syndrome, stage ivb mycosis fungoides/sezary syndrome